Latest Breaking News On - Biocept inc - Page 9 : comparemela.com

Investment Analysts Upgrades for October 5th (AMX, ATHM, ATLC, BECN, BIOC, CABGY, CAC, CCK, CDAY, CHSYF)

Investment Analysts’ upgrades for Thursday, October 5th: América Móvil (NYSE:AMX) was upgraded by analysts at Bank of America Co. from a neutral rating to a buy rating. Bank of America Co. currently has $25.00 target price on the stock, up from their previous target price of $23.00. Autohome (NYSE:ATHM) was upgraded by analysts at StockNews.com […]

United statesPernod ricardRaymond jamesLojas rennerPanmure gordonPiper sandlerRoyal bankJpmorgan chase coKelly servicesCitigroup incGoldman sachs group incGrupo televisaAmerica coCamden nationalNeedham companyUnited laboratories international

Cancer Biopsy Market will Grow at 14 7% CAGR and expected to cross US$ 67 11 Billion by 2030 | Hologic, Inc , Biocept, Inc , Thermo Fisher Scientific, Inc , Danaher, F Hoffmann-La Roche Ltd |

Cancer Biopsy Market will Grow at 14 7% CAGR and expected to cross US$ 67 11 Billion by 2030 | Hologic, Inc , Biocept, Inc , Thermo Fisher Scientific, Inc , Danaher, F Hoffmann-La Roche Ltd |
medgadget.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medgadget.com Daily Mail and Mail on Sunday newspapers.

United kingdomUniversity of central floridaBusiness developmentHologic incPorters five forces analysisThermo fisher scientific incGe healthcareHelio health laboratory for advanced medicineWorld health organizationCounsyl incDrug administrationFoundation medicine incRoche ltdTop companies associatedIllumina incBiocept inc

Precision Medicine Takes Center Stage: Innovative Report Explores the Role of Companion Diagnostics in Transforming Healthcare

/PRNewswire/ The "Companion Diagnostic Markets - the Future of Diagnostics by Application, Technology and Funding With Executive and Consultant Guides.

United statesSysmex inosticsCdx therascreenLaura woodSiemens healthineersVyant bioMiltenyi biotecAvalon globocareBristol myers squibbPerkin elmer revvityAgilent dakoCstone pharmaceuticals to codevelop cdxPublic nationalBiodesix incBioneer corporationE st office hours call

Enrollment Completed in the Feasibility Phase of the FORESEE Clinical Trial with Biocept s CNSide™ Assay to Evaluate Patients with Leptomeningeal Metastases

Biocept, Inc. , a leading provider of molecular diagnostic assays, products and services, announces the full enrollment of 40 subjects with breast or non-small cell lung cancer who have suspicious.

Jonathan yangNational comprehensive cancer networkExchange commissionUniversity of washingtonBiocept incAntonino moralesBiocept presidentPrivate securities litigation reform actQuarterly report

Prostate Cancer Diagnostics Market to hit USD 11 5 billion

Prostate Cancer Diagnostics Industry is projected to witness a CAGR of 12.4% during the period 2023-2032. This progression can be attributed to the increasing popularity of prostate cancer diagnostic tests.

United statesSouth koreaSouth koreanAsia pacificBiocept incQuest diagnosticsBecton dickinsonAbbott laboratoriesBrowse our reportsAgilent technologiesSiteman cancer centerAstrazeneca plcProstate cancer diagnostics marketInify laboratoriesReport customizationProstate cancer diagnostics industry